New biomarker identifies colon cancer patients who may benefit from chemotherapy

Using a new computer science approach, researchers at University of California, San Diego School of Medicine, Columbia University and Stanford University discovered a distinctive molecular feature -- a biomarker -- that identified colon cancer patients who were most likely to remain disease-free up to five years after surgery. The biomarker, a protein called CDX2, also helped the researchers identify Stage II colon cancer patients who are most likely to benefit from chemotherapy after surgery.

What feeling does this article give you?

#hashtags to follow:

Using [+]    California [+]    Stage II [+]   

More #news: